


When Can Duplex Ultrasound Fully Replace CT Surveillance After EVAR: When Is CT Surveillance Necessary?



Sal Scali, MD
Division of Vascular Surgery & Endovascular Therapy
University of Florida, Gainesville

Wednesday, November 20th, 2024 5:54-5:59PM
Session 46: More Short Hot New Topics Related to Aortic Disease




Disclosures

- None




Endovascular Aneurysm Repair

- EVAR is the **dominant** treatment strategy for infrarenal AAA repair in the US.
 - 70% - 80% *elective*
 - 30% - 45% *rupture*
- Postoperative surveillance is **mandatory** to ensure durability.
 - *imaging (CT, DUS, MRI, etc.)*



EVAR Failure Modes

- EVAR Reintervention ~20-30% @ 5-10 years postop



Columbo et al. J Vasc Surg, 2019



EVAR Surveillance & Guidelines

- Guidelines have different recommendations
 - Evidence level modest/poor
 - Role of DUS/CEUS poorly defined
 - No clear scenario when DUS supplants CT


If no endovascular imaging in 12 months (contrast CT or DUS)

Wanitschen et al. Eur J Vasc Endovasc Surg, 2024



EVAR LOSS TO FOLLOW-UP

- N = 19,962 Medicare Beneficiaries [2001-2008]



Schanzer et al. J Vasc Surg, 2015
Winkler et al. Circulation, 2020



CT vs. DUS EVAR SURVEILLANCE

CT	Benefits	Risks
	<ul style="list-style-type: none"> - Sensitivity & Specificity for EL - IFU - Regulators - Less variation 	<ul style="list-style-type: none"> - High cost - XRT - Renal risk
DUS	<ul style="list-style-type: none"> - Low cost - No XRT - Low renal risk 	<ul style="list-style-type: none"> - Sensitivity & Specificity for EL - Non-IFU - Regulators - High variation

CEUS improves sensitivity

Zaimi et al. J Vasc Med Biol 2018

ESSEA TRIAL

N = 500 patients, prospective, multicenter trial [2010-2015]

Primary outcome = diagnostic accuracy of DUS for 'major AAA-related morphological abnormality' [MARMA]

Overall DUS Outcomes

- Sensitivity = **39%** (95%CI 29-48)
- Specificity = **92%** (95%CI 90-95)
- Sensitivity in detecting MARMA = 71%
- Sensitivity in detecting T2EL + 2-5mm sac growth = **11%**
- Sensitivity in detecting T2EL + ≥ 5mm sac growth = **45%**
- Sensitivity in detecting T1/3 EL = 29% (vs. other studies >80%)

CEUS in 13% of cases

Sensitivity for MARMA = **36%** (95%CI 14-61) vs. 94% Cochrane Review

Bach-Baptiste et al. Circ Cardiovasc Imaging 2020
Karthikeyan et al. Br J Surg 2012
Abrasha et al. Cochrane Database Syst Rev 2017

WHEN IS DUS OK AFTER EVAR?

Since no Level I evidence and publication uncertainty

Need to define characteristics of DUS surveillance populations with good long-term outcome

Patient, Anatomic and AAA Morphological Variables need to be factored into the analysis

Need large sample size given groups & event rates

Uf

EVAR IMAGING AFTER 1ST YEAR

N = 12,199 VQI patients with Medicare Claims Match

Imaging Category	%
No imaging	8.5%
CT/MRI only	26.6%
DUS only	16.1%
Mixed >50% CT/MRI <50% DUS	17.3%
Mixed >50% DUS <50% CT/MRI	20.1%
Other	11.4%

Blecha et al. Ann Vasc Surg 2024

Freedom From Aorta Related Re-intervention, Conversion to Open and/or Rupture

Log-rank P < .001

Years of follow-up	Group 1 (None)	Group 2 (CT/MRI only)	Group 3 (US only)	Group 4 (Mixed)
2 years	1.4% (3.7.3%)	5.0% (3.0-8.2%)	1.5% (0.2-11.1%)	3.7% (2.3-6.0%)
5 years	4.5% (2.6-7.8%)	16.0% (13.5-18.9%)	5.8% (3.0-9.7%)	16.5% (14.7-18.5%)
10 years	-	30.7% (23.1-42.4%)	13.0% (9.3-17.1%)	30.8% (26.8-35.2%)

Estimated risk of composite outcome

Blecha et al. Ann Vasc Surg 2024

EVAR SURVEILLANCE: PATIENT CHARACTERISTICS

'DUS only' post-EVAR surveillance associated with:

- elective, older, lower BMI, male patients with smaller AAA (<6cm) without concurrent iliac aneurysm



Blecha et al. Ann Vasc Surg 2024

EVAR SURVEILLANCE: ENDOLEAK & SAC CHANGE

'DUS only' post-EVAR surveillance associated with:

no endoleak at 1-year follow-up &
>5mm decrease in AAA sac diameter


Blecha et al. Ann Vasc Surg. 2024

Summary

- Early and Late Complications of EVAR mandate continuous monitoring.
- EVAR surveillance missing in up to 50% patients after 3 years.
- Societal guidelines differ in surveillance recommendations.
- No clear consensus on EVAR imaging type/frequency.
- Surveillance protocols should be individualized to the patient & scenario, as well as institutional experience.

RCT?



Conclusions

- DUS can safely supplant CT imaging in selected patients. (no endoleak, normal BMI, sac regression at 1-year)
- CT required if sac growth on DUS (despite no endoleak) and/or evidence of endoleak.


Unresolved Questions:

- Role of intervention for T2EL with sac expansion.
- Long-term outcomes of risk-stratified surveillance strategies.

Future Research Needs:

- Investigate methods to improve ultrasound sensitivity & specificity.
- Develop standardized imaging protocols & sonographer training programs.
- Assess whether surveillance adherence impacts AAA-related mortality.

Takeaway: Optimizing surveillance remains vital to improve EVAR outcomes and minimize rupture risk



Thank You







